A detailed history of Black Rock Inc. transactions in Sera Prognostics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,409,871 shares of SERA stock, worth $11.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,409,871
Previous 118,964 1085.12%
Holding current value
$11.5 Million
Previous $1.08 Million 671.35%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$5.6 - $11.69 $7.23 Million - $15.1 Million
1,290,907 Added 1085.12%
1,409,871 $8.35 Million
Q1 2024

May 10, 2024

BUY
$5.05 - $10.0 $156,580 - $310,060
31,006 Added 35.25%
118,964 $1.08 Million
Q4 2023

Feb 13, 2024

BUY
$1.65 - $6.85 $50,042 - $207,753
30,329 Added 52.63%
87,958 $525,000
Q3 2023

Nov 13, 2023

SELL
$1.55 - $3.34 $3,547 - $7,645
-2,289 Reduced 3.82%
57,629 $107,000
Q2 2023

Aug 11, 2023

BUY
$3.0 - $3.98 $36,144 - $47,951
12,048 Added 25.17%
59,918 $197,000
Q1 2023

May 12, 2023

BUY
$1.19 - $4.25 $4,729 - $16,889
3,974 Added 9.05%
47,870 $183,000
Q4 2022

Feb 13, 2023

SELL
$1.16 - $1.8 $13,598 - $21,101
-11,723 Reduced 21.08%
43,896 $55,000
Q3 2022

Nov 14, 2022

BUY
$1.55 - $2.71 $1,771 - $3,097
1,143 Added 2.1%
55,619 $89,000
Q2 2022

Aug 12, 2022

SELL
$1.2 - $3.62 $157,996 - $476,623
-131,664 Reduced 70.73%
54,476 $90,000
Q1 2022

May 12, 2022

BUY
$2.96 - $8.8 $25,805 - $76,718
8,718 Added 4.91%
186,140 $707,000
Q4 2021

Feb 10, 2022

BUY
$6.87 - $11.41 $188,485 - $313,044
27,436 Added 18.29%
177,422 $1.22 Million
Q3 2021

Nov 09, 2021

BUY
$7.9 - $13.04 $1.18 Million - $1.96 Million
149,986 New
149,986 $1.67 Million

Others Institutions Holding SERA

About SERA PROGNOSTICS, INC.


  • Ticker SERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 29,596,900
  • Market Cap $242M
  • Description
  • Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product ...
More about SERA
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.